Ann: Sensera completes A$2.5m private placement, page-82

In the 31 May investor update presentation, Sensera stated:
'Based on the expected increase in orders and the reduced cost base of the business, Sensera is funded appropriately to transition to volume manufacturing'

There is a comment by Ralph in the 9 Dec 2020 AGM call that may give us a clue what part of the recent raise will be used for (14:30 mark onwards):
'In order to move the fab into a situation where it is more highly utilised, we will take some of the IP we develop which we have the rights to for each of these customers and then develop our own sensors and our expectation is to do that into next fiscal year' (this is July 2021 onwards ie potentially now).

If this is still the case, I'd expect news on this development this month.  Perhaps this has something to do with Schott MiniFab?

'Schott MiniFab Australian based MiniFab partners with clients to create and manufacture diagnostic and lifescience products. Schott are experts in microfluidic product design development and manufacturing. Schott AG has over 15,000 employees across 34 countries with revenues of EUR2bn. Sensera is collaborating to produce precision silicon master ‘micro-molds' that are used in integrated Organ-on-a Chip devices for drug discovery and development'.

In regards to the potential USD $2m loan from Pure, IMO this is strictly tied to the NanoDX EUA approval.

Cheers